AI Engines For more Details: Perplexity Kagi Labs You
Irritable Bowel Syndrome (IBS): Pinaverium bromide is commonly prescribed for the symptomatic relief of irritable bowel syndrome, a chronic gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. It works by relaxing the smooth muscles of the digestive tract, thereby reducing spasms and alleviating abdominal discomfort.
Functional Gastrointestinal Disorders: Pinaverium bromide may also be used to manage other functional gastrointestinal disorders, such as functional dyspepsia and functional abdominal pain. These conditions are characterized by chronic or recurrent gastrointestinal symptoms in the absence of organic or structural abnormalities.
Abdominal Pain and Discomfort: By exerting its antispasmodic effects on the smooth muscles of the gastrointestinal tract, pinaverium bromide helps alleviate abdominal pain, cramping, and discomfort associated with various gastrointestinal disorders.
Bloating and Gas: Pinaverium bromide may help reduce bloating and excessive gas production in individuals with functional gastrointestinal disorders, contributing to overall symptom relief and improved quality of life.
Regulation of Bowel Movements: In addition to relieving abdominal pain and discomfort, pinaverium bromide may help regulate bowel movements in individuals with IBS. By modulating intestinal motility and reducing smooth muscle hyperactivity, it can normalize bowel habits and decrease episodes of diarrhea or constipation.
Colon Spasms: Pinaverium bromide has been shown to effectively suppress abnormal contractions or spasms of the colon, which are commonly observed in individuals with IBS and other functional gastrointestinal disorders. By reducing colonic hypermotility, it can alleviate associated symptoms such as cramping and urgency.
Improvement in Quality of Life: The symptomatic relief provided by pinaverium bromide can lead to an overall improvement in the quality of life for individuals suffering from irritable bowel syndrome and other functional gastrointestinal disorders. By reducing gastrointestinal symptoms and discomfort, it allows patients to better manage their condition and engage in daily activities more comfortably.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.1 | 0.3 | 12.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.3 | 1.9 | 0.21 |
| Allergies | 4.4 | 1.3 | 2.38 |
| Allergy to milk products | 0.9 | 1 | -0.11 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.4 | 6.6 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 2.6 | |
| Ankylosing spondylitis | 3.6 | 0.9 | 3 |
| Anorexia Nervosa | 1.1 | 2.7 | -1.45 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
| Asthma | 4.2 | 1.8 | 1.33 |
| Atherosclerosis | 1.5 | 1.7 | -0.13 |
| Atrial fibrillation | 3.8 | 2.5 | 0.52 |
| Autism | 7.6 | 8.3 | -0.09 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.5 | 1.5 | |
| Bipolar Disorder | 1 | 1.1 | -0.1 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Cancer (General) | 0.6 | 2 | -2.33 |
| Carcinoma | 2.9 | 2.3 | 0.26 |
| Celiac Disease | 3 | 3.5 | -0.17 |
| Cerebral Palsy | 1.2 | 1 | 0.2 |
| Chronic Fatigue Syndrome | 3.4 | 7.1 | -1.09 |
| Chronic Kidney Disease | 3.7 | 2.9 | 0.28 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 1.7 | -0.13 |
| Chronic Urticaria (Hives) | 0.6 | 1.2 | -1 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 2.8 | 1.4 | 1 |
| Colorectal Cancer | 4.6 | 2 | 1.3 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 1.1 | 3 | -1.73 |
| COVID-19 | 7.1 | 10.3 | -0.45 |
| Crohn's Disease | 6.7 | 5.2 | 0.29 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.4 | -1.4 | |
| deep vein thrombosis | 0.9 | 1.1 | -0.22 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 9.2 | 8.4 | 0.1 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.9 | 1.3 | -0.44 |
| Endometriosis | 2.3 | 1.7 | 0.35 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.9 | 1.7 | 0.12 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 2.6 | 2.4 | 0.08 |
| Functional constipation / chronic idiopathic constipation | 5.2 | 4.1 | 0.27 |
| gallstone disease (gsd) | 2.3 | 0.8 | 1.87 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.2 | 0.25 |
| Generalized anxiety disorder | 1.3 | 1.8 | -0.38 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 0.3 | 3 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.7 | 1.4 | -1 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.3 | 1.8 | 0.83 |
| Heart Failure | 2.8 | 1.6 | 0.75 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.6 | 1.1 | -0.83 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.8 | 5.5 | -0.45 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 1.6 | 0.3 | 4.33 |
| IgA nephropathy (IgAN) | 1 | 4.9 | -3.9 |
| Inflammatory Bowel Disease | 5.1 | 7.9 | -0.55 |
| Insomnia | 1.9 | 2.1 | -0.11 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 5.6 | 4.8 | 0.17 |
| ischemic stroke | 2.3 | 1.1 | 1.09 |
| Liver Cirrhosis | 5.8 | 2.9 | 1 |
| Long COVID | 5.8 | 6.7 | -0.16 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 0.7 | -0.17 |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.9 | 2.4 | -1.67 |
| ME/CFS without IBS | 0.6 | 2.4 | -3 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.6 | 0.5 | 2.2 |
| Metabolic Syndrome | 5.5 | 7.2 | -0.31 |
| Mood Disorders | 8.7 | 6.7 | 0.3 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 4 | 5.9 | -0.48 |
| Multiple system atrophy (MSA) | 1.2 | 0.4 | 2 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 3.1 | -3.1 | |
| Neuropathy (all types) | 0.4 | 1.6 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.9 | 4.1 | -0.05 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 8.2 | 5.8 | 0.41 |
| obsessive-compulsive disorder | 5.2 | 3.9 | 0.33 |
| Osteoarthritis | 1.6 | 0.9 | 0.78 |
| Osteoporosis | 1.1 | 1.3 | -0.18 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 5.6 | 5.7 | -0.02 |
| Polycystic ovary syndrome | 5.5 | 2.1 | 1.62 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 2.5 | 2.3 | 0.09 |
| Psoriasis | 2.4 | 3.4 | -0.42 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6 | 4.2 | 0.43 |
| Rosacea | 0.9 | 0.5 | 0.8 |
| Schizophrenia | 5.1 | 2.6 | 0.96 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 2.6 | 2.8 | -0.08 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.6 | 1 |
| Stress / posttraumatic stress disorder | 2.1 | 2.1 | 0 |
| Systemic Lupus Erythematosus | 3.2 | 1.6 | 1 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.4 | 3.4 | 0 |
| Type 2 Diabetes | 6.9 | 6 | 0.15 |
| Ulcerative colitis | 3.8 | 7.1 | -0.87 |
| Unhealthy Ageing | 5.3 | 2.4 | 1.21 |
| Vitiligo | 2.2 | 1.3 | 0.69 |
